ClinicalTrials.gov
public full text
Public Domain
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's#1362811
- A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD#1196244
- A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease#844223
- MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)#802999
- Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase#895580
Record · ID 1246802
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive